您的位置: 首页 > 农业专利 > 详情页

TREATMENT OF CANCERS AND HEMATOPOIETIC STEM CELL DISORDERS PRIVILEGED BY CXCL12-CXCR4 INTERACTION
专利权人:
发明人:
Stephen Marcus
申请号:
US15044740
公开号:
US20160235779A1
申请日:
2016.02.16
申请国别(地区):
US
年份:
2016
代理人:
摘要:
Methods are presented for treating cancers and hematopoietic stem cell disorders, comprising administering to a subject with a cancer or hematopoietic stem cell disorder who is receiving a treatment regimen, a heparin derivative capable of inhibiting, reducing, abrogating or otherwise interfering with the binding of CXCL12 to CXCR4, wherein the cancer or hematopoietic stem cell disorder is one in which interaction of CXCL12 with CXCR4 privileges the cancer or disordered HSCs against therapeutic intervention. In preferred embodiments, the heparin derivative is a substantially 2-O, 3-O-desulfated heparin derivative.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充